Platelet function during extended prasugrel and clopidogrel therapy for patients with ACS treated without revascularization: The TRILOGY ACS platelet function substudy

JAMA

Volumn 308, Issue 17, 2012, Pages 1785-1794

  Gurbel, Paul A ^a   Erlinge, David ^b   Ohman, E Magnus ^c   Neely, Benjamin ^d   Neely, Megan ^d   Goodman, Shaun G ^e   Huber, Kurt ^f   Chan, Mark Y ^g   Cornel, Jan H ^h   Brown, Eileen ⁱ   Zhou, Chunmei ⁱ   Jakubowski, Joseph A ⁱ   White, Harvey D ^j   Fox, Keith A A ^k   Prabhakaran, Dorairaj ^l   Armstrong, Paul W ^m   Tantry, Udaya S ^a   Roe, Matthew T ^c  

^a SINAI CENTER FOR THROMBOSIS RESEARCH   (United States)

^b LUND UNIVERSITY   (Sweden)

^c DUKE UNIVERSITY MEDICAL CENTER   (United States)

^d DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^e ST MICHAEL'S HOSPITAL   (Canada)

^f WILHELMINEN HOSPITAL   (Austria)

^g NATIONAL UNIVERSITY HEALTH SYSTEM   (Singapore)

^h Location Alkmaar   (Netherlands)

ⁱ ELI LILLY AND COMPANY   (United States)

^j AUCKLAND CITY HOSPITAL   (New Zealand)

^k UNIVERSITY OF EDINBURGH   (United Kingdom)

^l CENTRE FOR CHRONIC DISEASE CONTROL   (India)

^m UNIVERSITY OF ALBERTA   (Canada)

more..

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84868332790     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2012.17312     Document Type: Article

References (15)

1. Gurbel PA, Bliden KP, Hayes KM, Tantry U. Platelet activation in myocardial ischemic syndromes. Expert Rev Cardiovasc Ther. 2004;2(4):535-545.
2. Gurbel PA, Tantry US. Do platelet function testing and genotyping improve outcome in patients treated with antithrombotic agents? platelet function testing and genotyping improve outcome in patients treated with antithrombotic agents. Circulation. 2012;125(10):1276-1287, discussion 1287.
3. Gurbel PA, Roe MT, Jakubowski JA, et al. Translational platelet research in patients with coronary artery disease: what are the major knowledge gaps? Thromb Haemost. 2012;108(1):12-20.
4. Aradi D, Komócsi A, Vorobcsuk A, et al. Prognostic significance of high on-clopidogrel platelet reactivity after percutaneous coronary intervention: systematic review and meta-analysis. Am Heart J. 2010; 160(3):543-551.
5. Price MJ, Berger PB, Teirstein PS, et al; GRAVITAS Investigators. Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial. JAMA. 2011;305(11):1097-1105.
6. Campo G, Parrinello G, Ferraresi P, et al. Prospective evaluation of on-clopidogrel platelet reactivity over time in patients treated with percutaneous coronary intervention relationship with gene polymorphisms and clinical outcome. J Am Coll Cardiol. 2011;57(25):2474-2483.
7. Roe MT, Armstrong PW, Fox KA, et al; TRILOGY ACS Investigators. Prasugrel versus clopidogrel for acute coronary syndromes without revascularization. N Engl J Med. 2012;367(14):1297-1309.
8. Jakubowski JA,Winters KJ, Naganuma H, Wallentin L. Prasugrel: a novel thienopyridine antiplatelet agent: a review of preclinical and clinical studies and the mechanistic basis for its distinct antiplatelet profile. Cardiovasc Drug Rev. 2007;25(4):357-374.
9. Eagle KA, Lim MJ, Dabbous OH, et al; GRACE Investigators. A validated prediction model for all forms of acute coronary syndrome: estimating the risk of 6-month postdischarge death in an international registry. JAMA. 2004;291(22):2727-2733.
10. Stone GW. Assessment of dual antiplatelet therapy with drug-eluting stents: a large-scale, prospective, multicenter registry examining the relationship between platelet responsiveness and stent thrombosis after DES implantation (ADAPT-DES). Presented at: Transcatheter Cardiovascular Therapeutics 23rd Annual Scientific Symposium; November 7-11, 2011; San Francisco, CA.
11. Trenk D, Stone GW, Gawaz M, et al. A randomized trial of prasugrel versus clopidogrel in patients with high platelet reactivity on clopidogrel after elective percutaneous coronary intervention with implantation of drug-eluting stents: results of the TRIGGER-PCI (Testing Platelet Reactivity In Patients Undergoing Elective Stent Placement on Clopidogrel to Guide Alternative Therapy With Prasugrel) study. J Am Coll Cardiol. 2012;59(24):2159-2164.
12. Erlinge D, Brown PB, Winters KJ, et al. Prasugrel 5 mg in the very elderly is non-inferior to prasugrel 10mg in non-elderly patients: the GENERATIONS trial, a pharmacodynamic (PD) study in stable CAD patients. Eur Heart J. 2012;33(suppl):675.
13. Erlinge D, Ten Berg J, Foley D, et al. Reduction in Platelet reactivity with prasugrel 5 mg in low-body-weight patients is noninferior to prasugrel 10 mg in higher-body-weight patients: results from the FEATHER trial [published online October 17, 2012]. J Am Coll Cardiol. doi:10.1016/j.jacc.2012.08.964.
14. Silvain J, Cayla G, Hulot JS, et al. High on-thienopyridine platelet reactivity in elderly coronary patients: the SENIOR-PLATELET study. Eur Heart J. 2012;33(10):1241-1249.
15. Wiviott SD, Trenk D, Frelinger AL, et al; PRINCIPLETIMI 44 Investigators. Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation-Thrombolysis in Myocardial Infarction 44 trial. Circulation. 2007;116(25):2923-2932.